Seizures in patients with multiple sclerosis: Epidemiology, pathophysiology and management

Brendan J. Kelley, Moses Rodriguez

Research output: Contribution to journalReview article

58 Citations (Scopus)

Abstract

Seizures have been recognized to occur in multiple sclerosis (MS) since early descriptions of the disease. Various studies have attempted to determine the incidence and prevalence of seizures in MS; although they differ in the reported prevalence, seizures do appear to be more common in MS cohorts than in the general population.The pathological underpinning of seizures in MS remains indeterminate. Cortical and subcortical demyelination and inflammation may explain the increased frequency of seizures in MS, although this hypothetical correlation remains to be proven.Management of seizures in MS is similar to the management of seizures in other patients. Consideration of the underlying neurological deficits related to MS may be necessary, and dosages of antiepileptic drugs should be adjusted if increased sensitivity to the adverse effects of these agents or interaction with other centrally acting medications is suspected. The prognosis of epilepsy in patients with MS remains uncertain, with some studies suggesting a more favourable prognosis than others.

Original languageEnglish (US)
Pages (from-to)805-815
Number of pages11
JournalCNS Drugs
Volume23
Issue number10
DOIs
StatePublished - Sep 21 2009

Fingerprint

Multiple Sclerosis
Epidemiology
Seizures
Demyelinating Diseases
Anticonvulsants
Epilepsy
Inflammation
Incidence
Population

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Clinical Neurology

Cite this

Seizures in patients with multiple sclerosis : Epidemiology, pathophysiology and management. / Kelley, Brendan J.; Rodriguez, Moses.

In: CNS Drugs, Vol. 23, No. 10, 21.09.2009, p. 805-815.

Research output: Contribution to journalReview article

@article{e5a29322e9244610843b01b5781115c6,
title = "Seizures in patients with multiple sclerosis: Epidemiology, pathophysiology and management",
abstract = "Seizures have been recognized to occur in multiple sclerosis (MS) since early descriptions of the disease. Various studies have attempted to determine the incidence and prevalence of seizures in MS; although they differ in the reported prevalence, seizures do appear to be more common in MS cohorts than in the general population.The pathological underpinning of seizures in MS remains indeterminate. Cortical and subcortical demyelination and inflammation may explain the increased frequency of seizures in MS, although this hypothetical correlation remains to be proven.Management of seizures in MS is similar to the management of seizures in other patients. Consideration of the underlying neurological deficits related to MS may be necessary, and dosages of antiepileptic drugs should be adjusted if increased sensitivity to the adverse effects of these agents or interaction with other centrally acting medications is suspected. The prognosis of epilepsy in patients with MS remains uncertain, with some studies suggesting a more favourable prognosis than others.",
author = "Kelley, {Brendan J.} and Moses Rodriguez",
year = "2009",
month = "9",
day = "21",
doi = "10.2165/11310900-000000000-00000",
language = "English (US)",
volume = "23",
pages = "805--815",
journal = "CNS Drugs",
issn = "1172-7047",
publisher = "Adis International Ltd",
number = "10",

}

TY - JOUR

T1 - Seizures in patients with multiple sclerosis

T2 - Epidemiology, pathophysiology and management

AU - Kelley, Brendan J.

AU - Rodriguez, Moses

PY - 2009/9/21

Y1 - 2009/9/21

N2 - Seizures have been recognized to occur in multiple sclerosis (MS) since early descriptions of the disease. Various studies have attempted to determine the incidence and prevalence of seizures in MS; although they differ in the reported prevalence, seizures do appear to be more common in MS cohorts than in the general population.The pathological underpinning of seizures in MS remains indeterminate. Cortical and subcortical demyelination and inflammation may explain the increased frequency of seizures in MS, although this hypothetical correlation remains to be proven.Management of seizures in MS is similar to the management of seizures in other patients. Consideration of the underlying neurological deficits related to MS may be necessary, and dosages of antiepileptic drugs should be adjusted if increased sensitivity to the adverse effects of these agents or interaction with other centrally acting medications is suspected. The prognosis of epilepsy in patients with MS remains uncertain, with some studies suggesting a more favourable prognosis than others.

AB - Seizures have been recognized to occur in multiple sclerosis (MS) since early descriptions of the disease. Various studies have attempted to determine the incidence and prevalence of seizures in MS; although they differ in the reported prevalence, seizures do appear to be more common in MS cohorts than in the general population.The pathological underpinning of seizures in MS remains indeterminate. Cortical and subcortical demyelination and inflammation may explain the increased frequency of seizures in MS, although this hypothetical correlation remains to be proven.Management of seizures in MS is similar to the management of seizures in other patients. Consideration of the underlying neurological deficits related to MS may be necessary, and dosages of antiepileptic drugs should be adjusted if increased sensitivity to the adverse effects of these agents or interaction with other centrally acting medications is suspected. The prognosis of epilepsy in patients with MS remains uncertain, with some studies suggesting a more favourable prognosis than others.

UR - http://www.scopus.com/inward/record.url?scp=70349108297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349108297&partnerID=8YFLogxK

U2 - 10.2165/11310900-000000000-00000

DO - 10.2165/11310900-000000000-00000

M3 - Review article

C2 - 19739692

AN - SCOPUS:70349108297

VL - 23

SP - 805

EP - 815

JO - CNS Drugs

JF - CNS Drugs

SN - 1172-7047

IS - 10

ER -